Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by losingmyshirton Jul 15, 2022 4:25pm

146 Views

Post# 34828010

WELL BOYS, LOOKS LIKE SHE'S DONE

SEEMS TO ME THAT THEY WERE SUPPOSED TO SUPPLY AN UPDATE AS PER THE MCTO BUT LOOKS LIKE THE LAST ONE WAS JUNE 24. EITHER LATE OR THE JIG IS FINALLY UP FOR THESE SHYSTERS.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023